The short version of Nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-15. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
== Reformulation == Percodan was reformulated in 2005; prior to 2005, it contained two oxycodone salts—4.62 mg of oxycodone hydrochloride and 0.38 mg of oxycodone terephthalate. Since the latter salt is unusual in the pharmacopeia, the manufacturer increased the amount of oxycodone hydrochloride to 4.8355 mg and discontinued the oxycodone terephthalate.
Alteplase binds to fibrin in a blood clot and activates the clot-bound plasminogen. Alteplase cleaves plasminogen at the site of its Arg561-Val562 peptide bond to form plasmin. Plasmin is a fibrinolytic enzyme that cleaves the cross-links between polymerized fibrin molecules, causing the blood clot to break down and dissolve, a process called fibrinolysis.
== Mechanism of action == Thiamazole inhibits the enzyme thyroperoxidase, which normally acts in thyroid hormone synthesis by oxidizing the anion iodide (I−) to iodine (I2), hypoiodous acid (HOI), and enzyme linked hypoiodate (EOI), facilitating iodine's addition to tyrosine residues on the hormone precursor thyroglobulin, a necessary step in the synthesis of triiodothyronine (T3) and thyroxine (T4). It does not inhibit the action of the sodium-dependent iodide transporter located on follicular cells' basolateral membranes. Inhibition of this step requires competitive inhibitors such as perchlorate and thiocyanate. A study has shown that it modulates secretion of CXCL10.
Encouraged by South Africa's apparent failure to detect the initial incursion, larger insurgent groups made their own infiltration attempts in February and March 1966. The second unit, "Group 2", was led by Leonard Philemon Shuuya, also known by the nom de guerre "Castro" or "Leonard Nangolo". Group 2 apparently become lost in Angola before it was able to cross the border, and the guerrillas dispersed after an incident in which they killed two shopkeepers and a vagrant. Three were arrested by the Portuguese colonial authorities in Angola, who were working off tips received from local civilians. Another eight, including Shuuya, had been captured between March and May by the South African police, apparently in Kavangoland. Shuuya later resurfaced at Kongwa, claiming to have escaped his captors after his arrest. He helped plan two further incursions: a third SWALA group entered Ovamboland that July, while a fourth was scheduled to follow in September.
Sources: en.wikipedia.org
== Analytical methods == Given the large diversity of PFAS structures that exist, analytical methods for PFAS analysis generally take one of two different approaches: targeted analysis or non-targeted analysis. Targeted methods narrow focus on known PFAS of concern (e.g. PFOA, PFOS) and generally use solid-phase extraction with liquid chromatography–mass spectrometry (LC-MS) detection. For example, EPA Method 537.1 is approved for use in drinking water and can quantify 18 PFAS compounds, while EPA Method 1633A is approved for use for wastewater, surface water, groundwater, soil, biosolids, sediment, landfill leachate, and fish tissue for 40 PFAS chemicals. Regulatory limits for PFOA and PFOS set by the US EPA (4 parts-per-trillion) are limited by the capability of targeted methods to detect low-level concentrations. Non-targeted analyses often sacrifice the identification and quantification of specific PFAS compounds to better understand the amount of PFAS present as a class. For example, total organic fluorine (TOF) analysis quantifies the amount of fluoride produced when a sample is oxidized at high enough temperatures to break the carbon-fluorine bond using combustion ion chromatography. Variants of this analysis include adsorbable organic fluorine (AOF) and extractable organic fluorine (EOF), which use similar solid-phase extraction approaches as the targeted analysis, but use combustion ion chromatography (CIC) as a detector.
The head of the Ukrainian Defense Industry claimed that Ukraine's production of suicide drones identical to Shahed 131s and Shahed 136s had caught up with Russia's production of Shahed drones. He also claimed that Ukrainian manufacturing reached parity with Russia's production of other strike drones, and that Ukrainian forces have already used domestically produced drones similar to Russia's Lancet drones.
Zircon contains high amount of uranium for machine recognition, commonly 100–1000 ppm. Zircon has a low amount of lead during crystallization, in parts per trillion. Thus, lead found in zircon can be assumed as daughter nuclei from parent uranium. Zircon crystals grow between 600 and 1100 °C, while lead is retained within the crystal structure below 800 °C (see Closure temperature). So once zircon has cooled below 800 °C it retains all the lead from the radioactive decay. Therefore, U-Pb age can be treated as the age of crystallization, if the mineral/sample itself has not undergone high temperature metamorphism after formation. Zircon commonly crystallizes in felsic igneous rocks, with greater than 60% silica (SiO2) content. These rocks are generally less dense and more buoyant. They sit high in the Earth's (continental crust), and have good preservation potential. Zircon is physically and chemically resistant, so it is more likely to be preserved in the sedimentary cycle. Zircon contains other elements which gives supplementary information, such as hafnium (Hf), uranium/thorium (U/Th) ratio.
The panel noted the large number of failures to replicate excess heat and the greater inconsistency of reports of nuclear reaction byproducts expected by established conjecture. Nuclear fusion of the type postulated would be inconsistent with current understanding and, if verified, would require established conjecture, perhaps even theory itself, to be extended in an unexpected way. The panel was against special funding for cold fusion research, but supported modest funding of "focused experiments within the general funding system". Cold fusion supporters continued to argue that the evidence for excess heat was strong, and in September 1990 the National Cold Fusion Institute listed 92 groups of researchers from 10 countries that had reported corroborating evidence of excess heat, but they refused to provide any evidence of their own arguing that it could endanger their patents. However, no further DOE nor NSF funding resulted from the panel's recommendation. By this point, academic consensus had moved decidedly toward labeling cold fusion as a kind of "pathological science". In March 1990, Michael H. Salamon, a physicist from the University of Utah, and nine co-authors reported negative results. University faculty were then "stunned" when a lawyer representing Pons and Fleischmann demanded the Salamon paper be retracted under threat of a lawsuit. The lawyer later apologized; Fleischmann defended the threat as a legitimate reaction to alleged bias displayed by cold-fusion critics.
The Times of India noted that these statements highlighted a disconnect between distributor-level performance and theatre-level earnings, suggesting that while certain distributors may have struggled due to high acquisition costs, individual cinemas in multiple territories were able to generate profits from theatrical screenings.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.